Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6356981 | 0.84 | PDE5A (0.38) | PDE5ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3579719 | 0.83 | SMN1; SMN2 (0.38) | PDE5ASMN1; SMN2 | |
| SCHEMBL6916828 | 0.82 | SMN1; SMN2 (0.35) | PDE5ASMN1; SMN2 | |
| SCHEMBL13500478 | 0.78 | ALDH1A1 (0.35) | PDE5ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6358740 | 0.76 | RAB9A (0.42) | MAPT | |
| SCHEMBL6200618 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6442557 | 0.74 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6629620 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL27492967 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5409423 | 0.71 | SMN1; SMN2 (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC | 2005-06-30 | — | — | US | disclosed |
| US-6809200-B2 | REACTING 5-ACETYL-N-(3-(AMINOCARBONYL)-5-ETHYL-1-(1-ETHYL-3-AZETIDINYL)-1H-PYRAZOL4 -YL)-2-ETHOXYNICOTINAMIDE, IN PRESENCE OF ALCOHOL OR ALKOXY COMPOUND AND A HYDROXIDE TRAPPING AGENT OR BASE | PFIZER INC. | 2004-10-26 | — | — | US | disclosed |
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC. | 2002-03-28 | — | — | US | disclosed |
| CN-1335317-A | Process for producing pyrazolo [4,3-d] pyrimidine-7-ketonic compound and its intermediate | PFIZER (US) | 2002-02-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | DPYD, HPRT1, SAMHD1 | PDE5A 1809/4885SMN1; SMN2 2390/4885ALDH1A1 480/4885 |
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | NOX4, VKORC1, DPYD | PDE5A 1588/4885SMN1; SMN2 2682/4885ALDH1A1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.